Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Endava plc (DAVA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Endava plc (NYSE:DAVA) on behalf of investors. The investigation follows Endava's announcement of its financial results for Q4 2023, which revealed the company was running behind its revenue trajectory by approximately £70 million, or nearly 9% below prior projections at the midpoint. This news caused Endava's American depositary share (ADS) price to fall $26.65 per ADS, or 41.76%, closing at $37.17 on February 29, 2024. Investors who purchased Endava securities are encouraged to participate in the investigation. The law firm is representing investors on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Bronstein, Gewirtz & Grossman sta indagando su potenziali richieste contro Endava plc (NYSE:DAVA) per conto degli investitori. L'indagine è stata avviata dopo l'annuncio dei risultati finanziari di Endava per il quarto trimestre del 2023, che ha rivelato che la società era in ritardo rispetto alle sue previsioni di fatturato di circa 70 milioni di sterline, ovvero quasi il 9% sotto le proiezioni precedenti al punto medio. Questa notizia ha causato una crescita del prezzo delle azioni depositarie americane (ADS) di Endava, che è sceso di $26.65 per ADS, ovvero del 41.76%, chiudendo a $37.17 il 29 febbraio 2024. Si incoraggiano gli investitori che hanno acquistato titoli Endava a partecipare all'indagine. Lo studio legale rappresenta gli investitori su base di pagamento in caso di successo, cercando il rimborso delle spese e delle spese legali solo se avrà esito positivo.
Bronstein, Gewirtz & Grossman está investigando posibles reclamos contra Endava plc (NYSE:DAVA) en nombre de los inversores. La investigación se inicia tras el anuncio de los resultados financieros de Endava para el cuarto trimestre de 2023, que reveló que la empresa estaba por detrás de su trayectoria de ingresos en aproximadamente £70 millones, o casi un 9% por debajo de las proyecciones anteriores en el punto medio. Esta noticia hizo que el precio de las acciones depositarias americanas (ADS) de Endava bajara $26.65 por ADS, o un 41.76%, cerrando a $37.17 el 29 de febrero de 2024. Se anima a los inversores que compraron valores de Endava a participar en la investigación. El bufete de abogados representa a los inversores en base a una tarifa de éxito, buscando reembolso de gastos y honorarios de abogados solo si tiene éxito.
Bronstein, Gewirtz & Grossman 이 투자자를 대신하여 Endava plc (NYSE:DAVA)에 대한 잠재적인 청구를 조사하고 있습니다. 이 조사는 Endava가 2023년 4 분기 재무 결과를 발표한 이후 시작되었으며, 이로 인해 회사가 약 7천만 파운드의 수익 목표에 뒤처져 있다는 것이 밝혀졌습니다. 이는 이전 중간 예측치보다 거의 9% 낮은 수치입니다. 이 소식은 Endava의 미국 예탁주식(ADS) 가격이 ADS당 $26.65, 즉 41.76% 하락하여 $37.17로 마감되었습니다 2024년 2월 29일. Endava의 증권을 구매한 투자자들은 조사가 진행되는데 참여할 것을 권장합니다. 법률 사무소는 성공할 경우에만 비용과 변호사 수임료를 청구하는 조건부 수수료 방식으로 투자자를 대리하고 있습니다.
Bronstein, Gewirtz & Grossman investigue des réclamations potentielles contre Endava plc (NYSE:DAVA) au nom des investisseurs. L'enquête fait suite à l'annonce des résultats financiers d'Endava pour le quatrième trimestre 2023, qui a révélé que l'entreprise était en retard par rapport à ses prévisions de revenus d'environ 70 millions de livres sterling, soit près de 9 % en dessous des prévisions antérieures au point médian. Cette nouvelle a entraîné une baisse du prix des actions déposées américaines (ADS) d'Endava, qui a chuté de 26,65 $ par ADS, soit 41,76 %, clôturant à 37,17 $ le 29 février 2024. Les investisseurs ayant acheté des titres Endava sont encouragés à participer à l'enquête. Le cabinet d'avocats représente les investisseurs sur une base de paiement sur résultat, recherchant le remboursement des frais et des honoraires d'avocat uniquement en cas de succès.
Bronstein, Gewirtz & Grossman untersucht potenzielle Ansprüche gegen Endava plc (NYSE:DAVA) im Namen von Investoren. Die Untersuchung folgt auf die Bekanntgabe der finanziellen Ergebnisse von Endava für das vierte Quartal 2023, die zeigte, dass das Unternehmen bei seinen Einnahmen um etwa 70 Millionen Pfund hinter den Prognosen zurückblieb, was fast 9% unter den vorherigen Schätzungen lag. Diese Nachricht führte dazu, dass der Preis für die amerikanischen Depotaktien (ADS) von Endava um $26.65 pro ADS, oder 41.76%, auf $37.17 fiel am 29. Februar 2024. Investoren, die Endava-Wertpapiere erworben haben, werden ermutigt, an dieser Untersuchung teilzunehmen. Die Kanzlei vertritt Investoren auf Erfolgsbasis und sucht die Erstattung von Kosten und Anwaltsgebühren nur im Erfolgsfall.
- None.
- Endava reported revenue approximately £70 million (9%) below projections
- Endava's ADS price fell 41.76% following the financial results announcement
- Potential legal claims against Endava for alleged wrongdoings
Insights
This investigation by Bronstein, Gewirtz & Grossman, into Endava plc (DAVA) is significant for investors. The key issue revolves around the company's financial results for Q4 2023, which fell short of projections by approximately
From a legal standpoint, the investigation aims to determine if there were any securities law violations or misrepresentations by Endava. If evidence of wrongdoing is found, it could lead to a class action lawsuit, potentially resulting in compensation for affected shareholders. However, it's important to note that at this stage, no formal accusations have been made and the investigation does not necessarily imply guilt.
Investors should closely monitor this situation, as the outcome could impact Endava's financial stability and future stock performance. It's advisable for shareholders to review their investment records and consider participating in the investigation if they believe they've been affected.
The substantial revenue miss and subsequent stock price plunge are major red flags for Endava. A
This situation raises questions about Endava's financial health and management credibility. Investors should scrutinize upcoming financial reports for any signs of systemic issues in revenue recognition, client retention, or market demand for Endava's services. The company's ability to provide accurate guidance and maintain transparency will be important for rebuilding trust.
Looking ahead, Endava may face challenges in accessing capital and maintaining growth if investor skepticism persists. The company needs to address the revenue shortfall transparently and present a clear plan for improving financial performance and forecasting accuracy to regain market confidence.
NEW YORK CITY, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Endava plc ("Endava" or "the Company") (NYSE:DAVA). Investors who purchased Endava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DAVA.
Investigation Details
On February 29, 2024, Endava announced its financial results for the three months ended December 31, 2023. Among other items, Endava stated that it was running behind its recent revenue trajectory by approximately £70 million, or nearly
What's Next?
If you are aware of any facts relating to this investigation or purchased Endava securities, you can assist this investigation by visiting the firm's site: bgandg.com/DAVA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on accesswire.com
FAQ
What caused Endava's (DAVA) stock price to drop on February 29, 2024?
Why is Bronstein, Gewirtz & Grossman investigating Endava (DAVA)?
How can Endava (DAVA) shareholders participate in the investigation?
What are the financial implications of Endava's (DAVA) Q4 2023 results?
